Development of novel nucleic acid aptamers for target specific therapy and diagnosis

We routinely develop novel nucleic acid aptamers -short DNA or RNA oligonucleotides that can bind to a specific molecular or cellular target with very high affinity and specificity similar to antibodies rendering the name ‘chemical antibodies’ against various targets including proteins, peptides and whole cells. We explore the potential of the developed aptamer for tissue specific drug delivery, targeted therapy, and targeted molecular imaging.

NMR structure of our

Aptamer RNV66 (PDB ID:2M53)

Computational prediction of

RNV66-VEGF binding

Our LNA-modifed

Aptamer RNV66​

Representative Publications:

1. All about Aptamer Technologies – Aptamer Book by Rakesh N. Veedu(2016)